Abstract
Objectives
Thrombophilia testing is commonly performed within hemostasis laboratories, and the ACL TOP 50 family of instruments represent a new ‘single platform’ of hemostasis instrumentation. The study objective was to evaluate these instruments and manufacturer reagents for utility of congenital thrombophilia assays.
Methods
Comparative evaluations of various congenital thrombophilia assays (protein C [PC], protein S [PS], antithrombin [AT], activated protein C resistance [APCR]) using newly installed ACL TOPs 550 and 750 as well as comparative assessments with existing, predominantly STAGO, instrumentation and reagents. Verification of manufacturer assay normal reference ranges (NRRs).
Results
HemosIL PC and free PS assays showed good comparability with existing Stago methods (R>0.9) and could be considered as verified as fit for purpose. HemosIL AT showed high relative bias with samples from patients on direct anti-Xa agents, compromising utility. Manufacturer NRRs for PC, PS and AT were verified with minor variance. Given the interference with direct anti-Xa agents, an alternate assay (Hyphen) was evaluated for AT, and the NRR also verified. The HemosIL Factor V Leiden (APC Resistance V) evidenced relatively poor performance compared to existing assays, and could not be adopted for use in our network.
Conclusions
This evaluation of HemosIL reagents on ACL TOP 50 family instruments identified overall acceptable performance of only two (PC, free PS) of four thrombophilia assays, requiring use of third-party reagents on ACL instruments for the other two assays (AT, APCR).
Acknowledgments
NSW Health Pathology is acknowledged for providing in-kind support to enable study completion. The views expressed herein are those of the authors and are not necessarily those of NSW Health Pathology.
-
Research funding: None declared.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Not applicable.
-
Ethical approval: Not Applicable. According to guidance from local Human Research Ethics Committees, formal ethical approval for this evaluation was not sought, as the evaluation represents a Quality Assurance project of method verification using patient samples in excess to needs and which would otherwise be discarded after testing and mandatory short-term storage according to local accreditation requirements.
References
1. Montagnana, M, Lippi, G, Danese, E. An overview of thrombophilia and associated laboratory testing. Methods Mol Biol 2017;1646:113–35. https://doi.org/10.1007/978-1-4939-7196-1_9.Search in Google Scholar PubMed
2. Favaloro, EJ, McDonald, D, Lippi, G. Laboratory evaluation of thrombophilia: the good, the bad and the ugly. Semin Thromb Hemost 2009;35:695–710.10.1055/s-0029-1242723Search in Google Scholar PubMed
3. Favaloro, EJ. The futility of thrombophilia testing. Clin Chem Lab Med 2014;52:499–503. https://doi.org/10.1515/cclm-2013-0560.Search in Google Scholar PubMed
4. Marlar, RA, Gausman, JN. Assessment of hereditary thrombophilia: performance of protein C (PC) testing. Methods Mol Biol 2017;1646:145–51. https://doi.org/10.1007/978-1-4939-7196-1_11.Search in Google Scholar PubMed
5. Marlar, RA, Gausman, JN. Assessment of hereditary thrombophilia: performance of protein S (PS) testing. Methods Mol Biol 2017;1646:153–60. https://doi.org/10.1007/978-1-4939-7196-1_12.Search in Google Scholar PubMed
6. Gausman, JN, Marlar, RA. Assessment of hereditary thrombophilia: performance of antithrombin (AT) testing. Methods Mol Biol 2017;1646:161–7. https://doi.org/10.1007/978-1-4939-7196-1_13.Search in Google Scholar PubMed
7. Favaloro, EJ, Mohammed, S, Vong, R, McVicker, W, Chapman, K, Swanepoel, P, et al.. Verification of the ACL Top 50 family (350, 550 and 750) for harmonisation of routine coagulation assays in a large network of 60 laboratories. Am J Clin Pathol 2021:aqab004. https://doi.org/10.1093/ajcp/aqab004.Search in Google Scholar PubMed
8. CLSI. Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline, 3rd ed. CLSI EPC28-A3c. Wayne (PA): Clinical and Laboratory Standards Institute; 2010.Search in Google Scholar
9. Milos, M, Herak, D, Kuric, L, Horvat, I, Zadro, R. Evaluation and performance characteristics of the coagulation system: ACL TOP analyzer – HemosIL reagents. Int J Lab Hematol 2009;31:26–35.10.1111/j.1751-553X.2007.00999.xSearch in Google Scholar
10. Ieko, M, Hotta, T, Watanabe, K, Adachi, T, Takeuchi, S, Naito, S, et al.. Comparative evaluation of reagents for measuring protein S activity: possibility of harmonization. Int J Hematol 2021;113:530–6.10.1007/s12185-020-03049-8Search in Google Scholar PubMed
11. Favaloro, EJ. More on ‘universal’ vs. ‘selected’ screening for thrombophilia: the hidden costs of false-positive diagnosis. Br J Haematol 2006;134:239–40.10.1111/j.1365-2141.2006.06138.xSearch in Google Scholar PubMed
12. Favaloro, EJ, Soltani, S, McDonald, J, Grezchnik, E, Easton, L. Laboratory identification of familial thrombophilia: do the pitfalls exceed the benefits? A reassessment of ABO-blood group, gender, age and other laboratory parameters on the potential influence on a diagnosis of protein C, protein S and antithrombin deficiency and the potential high risk of a false positive diagnosis. Lab Hematol 2005;11:174–84.10.1532/LH96.05029Search in Google Scholar PubMed
13. Curnow, J, Pasalic, L, Favaloro, EJ. Hereditary thrombophilias – pathophysiology, timing of testing and familial testing. In: Abutalib, SA, Connors, JM, Ragni, MV, editors. Non-malignant hematology – expert review. Switzerland AG: Springer International Publishers; 2016.10.1007/978-3-319-30352-9_41Search in Google Scholar
14. Favaloro, EJ. Danger of false negative (exclusion) or false positive (diagnosis) for ‘congenital thrombophilia’ in the age of anticoagulants. Clin Chem Lab Med 2019;57:873–82.10.1515/cclm-2018-1041Search in Google Scholar PubMed
15. Favaloro, EJ, Pasalic, L, Lippi, G. Oral anticoagulation therapy: an update on usage, costs and associated risks. Pathology 2020;52:736–41.10.1016/j.pathol.2020.05.006Search in Google Scholar PubMed
16. Dean, E, Favaloro, EJ. The changing face of activated protein C resistance testing—a 10-year retrospective. Ann Blood 2020;5:1–7. https://doi.org/10.21037/aob.2020.02.06.Search in Google Scholar
17. Favaloro, EJ, Gilmore, G, Bonar, R, Dean, E, Arunachalam, S, Mohammed, S, et al.. Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC stop to neutralise interference. Clin Chem Lab Med 2020;58:1322–31.10.1515/cclm-2019-1160Search in Google Scholar PubMed
18. Favaloro, EJ, Plebani, M, Lippi, G. Regulation in hemostasis and thrombosis: part I-in vitro diagnostics. Semin Thromb Hemost 2013;39:235–49. https://doi.org/10.1055/s-0033-1336833.Search in Google Scholar PubMed
19. Favaloro, EJ. Standardization, regulation, quality assurance and emerging technologies in hemostasis: issues, controversies, benefits, and limitations. Semin Thromb Hemost 2007;33:290–7. https://doi.org/10.1055/s-2007-971816.Search in Google Scholar PubMed
Supplementary Material
The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2021-0499).
© 2021 Walter de Gruyter GmbH, Berlin/Boston
